Q-omics provides the consensus-scored NMNAT1 profile across patient tissues and cancer cell-line models. NMNAT1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, NMNAT1 is differentially expressed in 11, with the highest sampling consensus in KICH. Additionally, NMNAT1 RNA expression shows 18,867 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRP, KICH, and ACC as cancer lineages where NMNAT1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NMNAT1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NMNAT1 survival associations across molecular data types. NMNAT1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NMNAT1 RNA expression–survival associations across cancer types. High NMNAT1 expression shows unfavorable associations in LGG and ACC, but favorable associations in KIRP, KIRC, STAD and SCLC. The KIRP Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for NMNAT1 RNA expression.
This table summarizes NMNAT1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 6. The strongest signals are observed in KICH for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for NMNAT1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NMNAT1 shows lower tumor expression in KICH, THCA, COAD, KIRC, KIRP and HNSC. The KICH box plot shows higher NMNAT1 RNA expression in normal versus tumor tissue (log2 FC = −0.908, t-test p < 0.001).
This table shows molecular features associated with NMNAT1 in patient tissues and cancer cell lines. In patient samples, NMNAT1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, NMNAT1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
